FORMULATION OF METHOTREXATE TOPICAL FORM ULATION (GEL) AND EVALUATION OF ITS IN VITRO TRANSDERMAL ABSORPTION

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

JAVADZADEH Y.; SIAHI M.R.; RAJABI ZOHREH; KEYVAN I.; SAFDARI REZVAN; ASNA ASHARI O.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: PHARMACEUTICAL SCIENCES Year:2008 | Volume:- | Issue:4 Page(s): 31-45

Download Full-Text

Persian Verion

View:

3,178

Download:

Cites:

Information Journal Paper

Title

FORMULATION OF METHOTREXATE TOPICAL FORM ULATION (GEL) AND EVALUATION OF ITS IN VITRO TRANSDERMAL ABSORPTION

Author(s)

Keywords

METHOTREXATEQ2

PERCUTANEOUS ABSORPTIONQ2

PSORIASISQ2

ENHANCERQ2

FORMULATIONQ2

Abstract

Objectives: PSORIASIS is a chronic, recurrent disease that affects between 1% and 6% of the population. METHOTREXATE (MTX) is an effective systemic chemotherapeutic agent for the treatment of PSORIASIS and possibly cutaneous lymphoma (CTCL).However the risk of hepatic fibrosis and other systemic toxicity, such as bone marrow suppression, has precluded its use in all but the most severe cases of these diseases. In considering the potential severe toxicity associated with systemic administration of MTX, a topical FORMULATION might be of greater utility for the treatment of PSORIASIS and other hyperproliferative skin disorders. One of the presumed reasons for the lack of clinical activity of topical METHOTREXATE in PSORIASIS is insufficient percutaneous penetration necessary to inhibit epidermal DNA synthesis. The present study was undertaken to prepare a FORMULATION to optimize penetration of MTX in vitro. Methods: For this mean, several gel FORMULATIONs were prepared and investigated in the case of stability and physical characteristics. Among them three FORMULATIONs were selected for PERCUTANEOUS ABSORPTION studies using rat skin and standard Franz diffusion cells. Assay of drug was done using HPLC method. For enhancing PERCUTANEOUS ABSORPTION, three penetration ENHANCERs were added to the bases FORMULATION with different concentrations. Among the evaluated FORMULATIONs, the best one from view point of having better penetration profile was selected and the effect of various ENHANCERs on penetration profile investigated. For this mean three surfactants (anionic, cationic and nonionic) were incorporated into FORMULATIONs with different concentrations. Finally salicylic acid as a keratolytic material was added for more enhancement effect. Results: The results showed that SLS (sodium louryl sulphate) and alkyl benzyl dimethyl chloride had not any significant enhancement property on penetration of MTX. Lower ability of these surfactants on drug penetration through the skin probably aroused from drug ENHANCER complexation and formation of micells with low penetration ability containing the drug molecules. Transcutol P was able to enhance transdermal absorption of MTX and the higher enhancement ratio was obtained with 2% (w/w) concentration of transcutol P. Adding of salicylic acid increased this ratio. Better penetration profile was shown with increasing of salicylic acid concentration. Conclusion: prepared FORMULATION containing transcutol p 2% (w/w) and salicylic acid 6% (w/w) had higher enhancement property and could be used clinically for local treatment of PSORIASIS.

Cites

No record.

References

FORMULATION OF TOPICAL FINASTERIDE AND EVALUATION OF ITS PERCUTANEOUS ABSORPTION

Cite

APA: Copy

JAVADZADEH, Y., SIAHI, M.R., RAJABI, ZOHREH, KEYVAN, I., SAFDARI, REZVAN, & ASNA ASHARI, O.. (2008). FORMULATION OF METHOTREXATE TOPICAL FORM ULATION (GEL) AND EVALUATION OF ITS IN VITRO TRANSDERMAL ABSORPTION. PHARMACEUTICAL SCIENCES, -(4), 31-45. SID. https://sid.ir/paper/48503/en

Vancouver: Copy

JAVADZADEH Y., SIAHI M.R., RAJABI ZOHREH, KEYVAN I., SAFDARI REZVAN, ASNA ASHARI O.. FORMULATION OF METHOTREXATE TOPICAL FORM ULATION (GEL) AND EVALUATION OF ITS IN VITRO TRANSDERMAL ABSORPTION. PHARMACEUTICAL SCIENCES[Internet]. 2008;-(4):31-45. Available from: https://sid.ir/paper/48503/en

IEEE: Copy

Y. JAVADZADEH, M.R. SIAHI, ZOHREH RAJABI, I. KEYVAN, REZVAN SAFDARI, and O. ASNA ASHARI, “FORMULATION OF METHOTREXATE TOPICAL FORM ULATION (GEL) AND EVALUATION OF ITS IN VITRO TRANSDERMAL ABSORPTION,” PHARMACEUTICAL SCIENCES, vol. -, no. 4, pp. 31–45, 2008, [Online]. Available: https://sid.ir/paper/48503/en

Related Journal Papers